Grundläggande statistik
| CIK | 1704287 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bluejay Diagnostics, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiz |
|
| August 11, 2025 |
Exhibit 99.1 Bluejay Diagnostics Provides Second Quarter Business and Corporate Update ACTON, MA – August 7, 2025 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program an |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluejay Di |
|
| July 28, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizat |
|
| July 28, 2025 |
Exhibit 10.1 AMENDMENT TO LICENSE AGREEMENT AND MASTER SUPPLY AGREEMENT This Amendment to License Agreement and Master Supply Agreement (this “Amendment”) is made as of July 22, 2025 (the “Amendment Effective Date”) by and between Bluejay Diagnostics, Inc., having its principal place of business at 360 Massachusetts Avenue, Suite 203, Acton, MA, 01720, USA (“Bluejay”) and Toray Industries, Inc., h |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 18, 2025 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizat |
|
| June 4, 2025 |
Exhibit 99.1 Bluejay Diagnostics Provides Mid-Year Business and Corporate Update ACTON, Mass., June 3, 2025 — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update. Recent Business Highlights and Developments: ● SYMON Clinica |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizati |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 28, 2025 |
Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement”) is being entered into by and between Bluejay Diagnostics, Inc. (the “Company”) and Jason Cook (“Executive”). The Company and Executive may hereafter be referred to individually as a “Party” or collectively as the “Parties.” Capitalized terms used but not otherwise defined herein sh |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizati |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 13, 2025 |
Exhibit 10.1 SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release (this “Agreement”), dated as of May 8, 2025, is entered into by and between Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), and Nanohybrids, Inc., a Delaware corporation (“Nanohybrids”). Jason Cook (the “Control Party”) joins this Agreement for the limited purposes set forth herein. Each of the p |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluejay D |
|
| May 8, 2025 |
BLUEJAY DIAGNOSTICS, INC. 1,085,106 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-286834 Prospectus BLUEJAY DIAGNOSTICS, INC. 1,085,106 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” or the Selling Stockholders, of up to 1,085,106 shares of our common stock, par value $0.0001 per sha |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| May 5, 2025 |
Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 May 5, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Bluejay Diagnostics, Inc. Registration Statement on Form S-3 File No. 333-286834 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules |
|
| April 29, 2025 |
As filed with the Securities and Exchange Commission on April 29, 2025 As filed with the Securities and Exchange Commission on April 29, 2025 Registration Statement No. |
|
| April 29, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Bluejay Diagnostics, Inc. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41031 Bluejay Diagnostics, Inc. (E |
|
| April 9, 2025 |
Exhibit 99.1 IMMEDIATE RELEASE Date: April 7, 2025 Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds ACTON, Mass., April 7, 2025 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care |
|
| April 9, 2025 |
Exhibit 10.1 Bluejay Diagnostics, Inc. April 7, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Warrants Dear Holder: Bluejay Diagnostics, Inc. (the “Company”) is pleased to offer to you (the “Holder”) the opportunity to exercise all of the Class C Common Stock Purchase Warrants, with an initial issuance date of June 28, 2024, exercisable for the Company’s shares of |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 7, 2025 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizat |
|
| April 9, 2025 |
Form of Class E Common Stock Purchase Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 31, 2025 |
Exhibit 19.1 Bluejay Diagnostics, Inc. Insider Trading Policy Effective March 24, 2025 Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Bluejay Diagnostics, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company engages in transactions or does business. The |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41031 Bluejay Diagnostics, Inc. (Exact Name of Registr |
|
| March 31, 2025 |
Description of Securities of Bluejay Diagnostics, Inc. Exhibit 4.10 DESCRIPTION OF CAPITAL STOCK The summary of general terms and provisions of our capital stock set forth below does not purport to be complete and is subject to and qualified by reference to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and Amended and Restated Bylaws (the “Bylaws,” and together with the Certificate of Incorporatio |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 3, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| November 18, 2024 |
Bluejay Diagnostics Announces Reverse Stock Split Exhibit 99.1 Bluejay Diagnostics Announces Reverse Stock Split ACTON, Mass., November 13, 2024 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of it |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 15, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organ |
|
| November 18, 2024 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF BLUEJAY DIAGNOSTICS, INC. Bluejay Diagnostics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Laws (the “DGCL”), does hereby certify as follows: FIRST: The name of the Corporation is Bluejay Diagnosti |
|
| November 14, 2024 |
BJDX / Bluejay Diagnostics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-bjdx093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bluejay Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 095633400 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 14, 2024 |
EX-99.1 2 d850844dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value, of Bluejay Diagnostics, Inc., a Delaware corp |
|
| November 14, 2024 |
BJDX / Bluejay Diagnostics, Inc. / Anson Funds Management LP - SC 13G Passive Investment SC 13G 1 d850844dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) BLUEJAY DIAGNOSTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 095633400 (CUSIP |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluej |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 23, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| October 16, 2024 |
Amendment No. 1 to Amended and Restated Bylaws Exhibit 3.1 Amendment No. 1 to Amended and Restated Bylaws of BlueJay Diagnostics, Inc. (a Delaware corporation) Pursuant to Article X of the Amended and Restated Bylaws (the “Bylaws”) of the Company, the Bylaws were amended by unanimous approval of the members of the Board of Directors of the Company as follows: 1. Section 2.7 of the Bylaws is hereby deleted in its entirety and replaced with the |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 16, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 28, 2024 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF BLUEJAY DIAGNOSTICS, INC. Bluejay Diagnostics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Laws (the “DGCL”), does hereby certify as follows: FIRST: The name of the Corporation is Bluejay Diagnosti |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 23, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiz |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 21, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiz |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluejay Di |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 3, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Bluejay Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 095633400 (CUSIP Number) June 27, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| June 28, 2024 |
Exhibit 4.2 CLASS C WARRANT TO PURCHASE COMMON STOCK BLUEJAY DIAGNOSTICS, INC. Warrant Shares: [●] Issuance Date: [●], 2024 THIS CLASS C WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Ini |
|
| June 28, 2024 |
Filed Pursuant to Rule 424(b)(1) Registration Statement No. 333-280253 Prospectus BLUEJAY DIAGNOSTICS, INC. 5,368,098 Units Each Consisting of One Share of Common Stock or One Prefunded Warrant to Purchase One Share of Common Stock, Two Class C Warrants each to Purchase One Share of Common Stock and One Class D Warrant to Purchase such number of Shares of Common Stock as determined in the Class D |
|
| June 28, 2024 |
Exhibit 1.1 Underwriting Agreement June 27, 2024 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 5,368,098 of the Company |
|
| June 28, 2024 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK BLUEJAY DIAGNOSTICS, INC. Warrant Shares: [●] Initial Exercise Date: [●], 2024 Issue Date: [●], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fo |
|
| June 28, 2024 |
Exhibit 4.3 Bluejay Diagnostics, Inc. Class D Warrant To Purchase Common Shares Warrant No.: Number of Common Shares: The Maximum Eligibility Number Date of Issuance: [●] (“Issuance Date”) Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the register |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 27, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizat |
|
| June 28, 2024 |
Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering Exhibit 99.1 Date: June 27, 2024 Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering ACTON, Mass., June 27, 2024 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a firm commit |
|
| June 28, 2024 |
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering Exhibit 99.2 Date: June 28, 2024 Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering ACTON, Mass., June 28, 2024 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commit |
|
| June 25, 2024 |
June 25, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 25, 2024 |
Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 June 25, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Bluejay Diagnostics, Inc. Registration Statement on Form S-1, as amended File No. 333-280253 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the |
|
| June 24, 2024 |
Exhibit 4.13 Bluejay Diagnostics, Inc. Class D Warrant To Purchase Common Shares Warrant No.: Number of Common Shares: The Maximum Eligibility Number Date of Issuance: [●] (“Issuance Date”) Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registe |
|
| June 24, 2024 |
As filed with the Securities and Exchange Commission on June 24, 2024 As filed with the Securities and Exchange Commission on June 24, 2024 Registration Statement No. |
|
| June 24, 2024 |
Exhibit 4.12 CLASS C WARRANT TO PURCHASE COMMON STOCK BLUEJAY DIAGNOSTICS, INC. Warrant Shares: [●] Issuance Date: [●], 2024 THIS CLASS C WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the In |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 17, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizat |
|
| June 20, 2024 |
Bluejay Diagnostics Announces Reverse Stock Split Exhibit 99.1 Bluejay Diagnostics Announces Reverse Stock Split ACTON, Mass., June 17, 2024 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its sh |
|
| June 20, 2024 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, OF BLUEJAY DIAGNOSTICS, INC. Bluejay Diagnostics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Laws (the “DGCL”), does hereby certify as follows: FIRST: The name of the Corporation is Bluejay Diagnosti |
|
| June 17, 2024 |
Exhibit 4.12 CLASS C WARRANT TO PURCHASE COMMON STOCK BLUEJAY DIAGNOSTICS, INC. Warrant Shares: [●] Issuance Date: [●], 2024 THIS CLASS C WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the In |
|
| June 17, 2024 |
Exhibit 4.13 Bluejay Diagnostics, Inc. Class D Warrant To Purchase Common Shares Warrant No.: Number of Common Shares: The Maximum Eligibility Number Date of Issuance: [●] (“Issuance Date”) Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registe |
|
| June 17, 2024 |
Exhibit 4.11 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK BLUEJAY DIAGNOSTICS, INC. Warrant Shares: [●] Initial Exercise Date: [●], 2024 Issue Date: [●], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| June 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) BLUEJAY DIAGNOSTICS, INC. |
|
| June 17, 2024 |
As filed with the Securities and Exchange Commission on June 17, 2024 As filed with the Securities and Exchange Commission on June 17, 2024 Registration Statement No. |
|
| June 17, 2024 |
Form of Underwriting Agreement Exhibit 1.1 Underwriting Agreement [●], 2024 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] of the Company’s units ( |
|
| May 31, 2024 |
Form of Senior Secured Note, dated June 3, 2024 Exhibit 10.3 [FORM OF SENIOR SECURED NOTE] THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURI |
|
| May 31, 2024 |
Form of Securities Purchase Agreement, dated May 31, 2024 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 31, 2024, between Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 31, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizati |
|
| May 31, 2024 |
Form of Note Purchase Agreement, dated May 31, 2024 Exhibit 10.1 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”) is dated as of May 31, 2024, between Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth i |
|
| May 16, 2024 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLUEJAY DIAGNOSTICS, INC. Bluejay Diagnostics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Laws (the “DGCL”), does hereby certify as follows: FIRST: The name of the Corporation is Bluejay Diagnostics, Inc., the |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 14, 2024 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizati |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluejay D |
|
| April 15, 2024 |
DEF 14A 1 ea0202939-02.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate b |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41031 Bluejay Diagnostics, Inc. (Exact Name of Registr |
|
| March 28, 2024 |
Exhibit 4.10 DESCRIPTION OF CAPITAL STOCK The summary of general terms and provisions of our capital stock set forth below does not purport to be complete and is subject to and qualified by reference to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and Amended and Restated Bylaws (the “Bylaws,” and together with the Certificate of Incorporatio |
|
| March 28, 2024 |
Incentive Compensation Recovery Policy Exhibit 97.1 BLUEJAY DIAGNOSTICS, Inc. Incentive Compensation Recovery Policy Introduction Bluejay Diagnostics, Inc. (the “Company”) has adopted this Incentive Compensation Recovery Policy (this “Policy”) to foster a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy with respect to executive compensation. This Policy |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organ |
|
| February 14, 2024 |
US0956333019 / BLUEJAY DIAGNOSTICS INC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-bjdx123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bluejay Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 095633301 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check th |
|
| January 2, 2024 |
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering Exhibit 99.1 Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering ACTON, Mass., December 28, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a public offering of 2,692,308 shares of th |
|
| January 2, 2024 |
Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 27, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organ |
|
| January 2, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 27, 2023, between Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| January 2, 2024 |
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering Exhibit 99.2 Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering ACTON, Mass., January 2, 2024 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of its previously announced public offering of 2 |
|
| January 2, 2024 |
Exhibit 4.2 COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set f |
|
| January 2, 2024 |
Form of January 2024 Placement Agent Common Stock Warrant Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Issue Date: January 2, 2024 Initial Exercise Date: January 2, 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafte |
|
| December 29, 2023 |
Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-275697 Prospectus BLUEJAY DIAGNOSTICS, INC. 537,768 Shares of Common Stock Prefunded Warrants to purchase up to 2,154,540 Shares of Common Stock Common Warrants to purchase up to 2,692,308 Shares of Common Stock 4,846,848 Shares of Common Stock underlying Prefunded Warrants and Common Warrants Placement Agent Warrants to Purchase up t |
|
| December 27, 2023 |
Exhibit 10.16 Execution Version August 7, 2023 STRICTLY CONFIDENTIAL Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 Attn: Neil Dey, Chief Executive Officer Dear Mr. Dey: This letter agreement (this “Agreement”) constitutes the agreement between Bluejay Diagnostics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the |
|
| December 27, 2023 |
Exhibit 10.17 Execution Version October 11, 2023 STRICTLY CONFIDENTIAL Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 Attn: Neil Dey, Chief Executive Officer Dear Mr. Dey: Reference is made to the engagement letter (the “Engagement Letter”), dated August 7, 2023, by and between Bluejay Diagnostics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), p |
|
| December 27, 2023 |
As filed with the Securities and Exchange Commission on December 27, 2023 As filed with the Securities and Exchange Commission on December 27, 2023 Registration Statement No. |
|
| December 27, 2023 |
Exhibit 99.1 IMMEDIATE RELEASE Date: December 27, 2023 Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec 27, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJD |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 27, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organ |
|
| December 22, 2023 |
December 22, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Bluejay Diagnostics, Inc. Registration Statement on Form S-1 (Registration No. 333-275697), as amended - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering |
|
| December 22, 2023 |
Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 December 22, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Bluejay Diagnostics, Inc. Registration Statement on Form S-1, as amended File No. 333-275697 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of |
|
| December 21, 2023 |
Form of Placement Agent Warrant Exhibit 4.9 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Issue Date: , 2023 Initial Exercise Date: , 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an |
|
| December 21, 2023 |
Form of Securities Purchase Agreement Exhibit 10.13 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2023, between Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| December 21, 2023 |
As filed with the Securities and Exchange Commission on December 21, 2023 As filed with the Securities and Exchange Commission on December 21, 2023 Registration Statement No. |
|
| December 21, 2023 |
Exhibit 4.7 PREFUNDED COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| December 21, 2023 |
Exhibit 4.8 COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set f |
|
| November 21, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BLUEJAY DIAGNOSTICS, INC. |
|
| November 21, 2023 |
As filed with the Securities and Exchange Commission on November 21, 2023 As filed with the Securities and Exchange Commission on November 21, 2023 Registration Statement No. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluej |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 9, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| November 9, 2023 |
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results Exhibit 99.1 Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results Acton, Massachusetts, November 9, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its finan |
|
| November 9, 2023 |
Exhibit 10.2 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement”) is being entered into by and between Bluejay Diagnostic, Inc. (the “Company”) and Kenneth R. Fisher (“Executive”). The Company and Executive may hereafter be referred to individually as a “Party” or collectively as the “Parties.” Capitalized terms used but not otherwise defined her |
|
| October 26, 2023 |
Exhibit 10.2 Bluejay Diagnostics, Inc. - and - Toray Industries, Inc. Master Supply Agreement Contents CLAUSE PAGE 1. Definitions 1 2. Sales and Purchase of Toray Chip Intermediates 4 3. Purchase orders 4 4. forecasts and production guarantees 5 5. Price 5 6. Payment 6 7. Quality Assurance, Acceptance and Delivery 6 8. Term and termination 8 9. Representations, Warranties, and Disclaimers 9 10. In |
|
| October 26, 2023 |
Exhibit 10.1 Amended and Restated License Agreement This Amended and Restated License Agreement (this “Agreement”) is made as of the 20th of October, 2023 (the “A&R Effective Date”) by and between Bluejay Diagnostics, Inc., having its principal place of business at 360 Massachusetts Avenue, Suite 203, Acton, MA, 01720, USA (“Bluejay”) and Toray Industries, Inc., having its principal place of busin |
|
| October 26, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2023 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 BLUEJAY DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Orga |
|
| August 28, 2023 |
Bluejay Diagnostics, Inc. 216,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-272432 PROSPECTUS SUPPLEMENT (To Prospectus dated June 20, 2023) Bluejay Diagnostics, Inc. 216,000 Shares of Common Stock We are offering 216,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), directly to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 24, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiz |
|
| August 28, 2023 |
Exhibit 99.1 Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The- Market under Nasdaq Rules ACTON, Mass., August 25, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entere |
|
| August 28, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 24, 2023, between Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| August 28, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 16, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiz |
|
| August 16, 2023 |
Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results Exhibit 99.1 Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results ACTON, Mass., August 16, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, announced financial results for the six months end |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluejay Di |
|
| August 10, 2023 |
Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement ACTON, Mass., August 9, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, announced today that on August 8, 2023, it received a notification |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 8, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 21, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizat |
|
| July 21, 2023 |
Bluejay Diagnostics Announces Reverse Stock Split Exhibit 99.1 Bluejay Diagnostics Announces Reverse Stock Split ACTON, Mass., July 21, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its sh |
|
| July 21, 2023 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLUEJAY DIAGNOSTICS, INC. Bluejay Diagnostics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Laws (the “DGCL”), does hereby certify as follows: FIRST: The name of the Corporation is Bluejay Diagnostics, Inc., the |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 14, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizat |
|
| June 15, 2023 |
Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 (844) 327-7078 Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 (844) 327-7078 June 15, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Jordan Nimitz Re: Bluejay Diagnostics, Inc Registration Statement on Form S-3 (File No. 333-272432) Request for |
|
| June 5, 2023 |
Form of Senior Debt Indenture. Exhibit 4.4 INDENTURE DATED AS OF , 20 BETWEEN BLUEJAY DIAGNOSTICS, INC. as Issuer, AND as Trustee Providing for Issuance of Senior Debt Securities in Series Table of Contents Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions. 1 Section 1.02 Compliance Certificates and Opinions. 6 Section 1.03 Form of Documents Delivered to Trustee. 6 Section 1.04 A |
|
| June 5, 2023 |
Form of Subordinated Debt Indenture. Exhibit 4.6 INDENTURE DATED AS OF , 20 BETWEEN BLUEJAY DIAGNOSTICS, INC. as Issuer, AND as Trustee Providing for Issuance of Subordinated Debt Securities in Series Table of Contents Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions. 1 Section 1.02 Compliance Certificates and Opinions. 6 Section 1.03 Form of Documents Delivered to Trustee. 6 Section |
|
| June 5, 2023 |
As filed with the Securities and Exchange Commission June 5, 2023 S-3 1 ea179778-s3bluejaydia.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission June 5, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Bluejay Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3552922 (State or |
|
| June 5, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bluejay Diagnostics, Inc. |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 19, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizati |
|
| May 19, 2023 |
Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy Exhibit 99.1 Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy ACTON, Mass., May 19, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced an updated clinical and regulatory strategy for the Symphony IL-6 bioma |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluejay D |
|
| May 10, 2023 |
Bluejay Diagnostics Reports First Quarter 2023 Financial Results Exhibit 99.1 Bluejay Diagnostics Reports First Quarter 2023 Financial Results ACTON, Mass., May 10, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today announced financial results for the quarter ended March 31, 2023. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 10, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizati |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41031 Bluejay Diagnostics, Inc. (E |
|
| April 27, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 25, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 20, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41031 Bluejay Diagnostics, Inc. (Exact Name of Registr |
|
| March 20, 2023 |
Bluejay Diagnostics Reports 2022 Financial Results Exhibit 99.1 Bluejay Diagnostics Reports 2022 Financial Results ACTON, Mass., March 20, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the year ended December 31, 2022. “Signifi |
|
| January 27, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into and effective as of January 27 2023 by and between Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”) and Neil Dey (the “Executive”, and the Company and the Executive collectively referred to herein as the “Parties”). WHEREAS, the Company and the Execu |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 27, 2023 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluej |
|
| November 8, 2022 |
Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results Exhibit 99.1 Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results Acton, Massachusetts, October 25, 2022 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its finan |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 8, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 25, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluejay Di |
|
| July 26, 2022 |
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results Exhibit 99.1 IMMEDIATE RELEASE Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results Acton, Massachusetts, July 26, 2022 ? Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (?Bluejay? or the ?Company?), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced financial results for the qu |
|
| July 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 26, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizat |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 9, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organizati |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluejay D |
|
| April 20, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 20, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| April 20, 2022 |
Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results Exhibit 99.1 IMMEDIATE RELEASE Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results Acton, Massachusetts, April 20, 2022 ? Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (?Bluejay?, ?the Company?), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial resul |
|
| April 19, 2022 |
EX-FILING FEES 6 ea158594ex-feebluejaydia.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price |
|
| April 19, 2022 |
2018 Equity Incentive Plan of Bluejay Diagnostics, Inc. Exhibit 99.2 BLUEJAY DIAGNOSTICS, INC. 2018 EQUITY INCENTIVE PLAN 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the BLUEJAY 2018 Equity Incentive Plan (the ?Plan?). The purposes of the Plan are to (a) enable the company (the ?Company?), to attract and retain the types of Employees, Consultants and Directors who will contribute to the Company?s long range success; (b) provi |
|
| April 19, 2022 |
As filed with the Securities and Exchange Commission on April 19, 2022 As filed with the Securities and Exchange Commission on April 19, 2022 Registration No. |
|
| April 19, 2022 |
Exhibit 99.1 BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN Section 1. Establishment and Purpose. 1.1 The Board of Directors of Bluejay Diagnostics, Inc. (the ?Company?) hereby establishes the Bluejay Diagnostics, Inc. 2021 Stock Plan (the ?Plan?) effective as of July 6, 2021, subject to approval by the Company?s stockholders within one year of the date hereof. 1.2 The purpose of the Plan is to attract |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 30, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| April 1, 2022 |
Separation Agreement between Bluejay Diagnostics, Inc. and Gordon Kinder Exhibit 10.1 March 23, 2022 Gordon W. Kinder [*] [*] [*] Re: Separation Agreement Dear Gordon: This letter, when it becomes effective, will constitute the Separation Agreement (the ?Agreement?) between you and Bluejay Diagnostic, Inc. (?the Company?) and contains the terms of your separation from employment with the Company. 1. Separation from Employment. Your employment with the Company will end |
|
| March 28, 2022 |
Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer Exhibit 99.1 IMMEDIATE RELEASE Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer Acton, Massachusetts. March 24, 2022 ? Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (?Bluejay?, ?the Company?) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Kenneth |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 23, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| March 28, 2022 |
Employment Agreement, dated March 23, 2022, between Kenneth Fisher and Bluejay Diagnostics, Inc. Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of March 23, 2022 (the ?Effective Date?), by and between Bluejay Diagnostic, Inc., a Delaware corporation (the ?Company?) having its principal place of business at 360 Massachusetts Ave, Acton, MA 01720, and Kenneth R. Fisher (?Executive?, and the Company and the Executive collectively referred to here |
|
| March 10, 2022 |
Exhibit 4.6 DESCRIPTION OF THE COMPANY?S SECURITIES The following summary is a description of the material terms of our capital stock. This summary is not complete, and is qualified by reference to our amended and restated certificate of incorporation, and our amended and restated bylaws, which are filed as exhibits to this Annual Report on Form 10-K and are incorporated by reference herein. We en |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41031 Bluejay Diagnostics, Inc. (Exact Name of Registr |
|
| March 10, 2022 |
Exhibit 99.1 IMMEDIATE RELEASE Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022 2021 ended with approximately $19 million in cash expected to fund operations beyond the date of our anticipated |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 10, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organiza |
|
| January 31, 2022 |
Exhibit 99.1 IMMEDIATE RELEASE Date: January 31, 2022 Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA Acton, Massachusetts, January 31, 2022 ? Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (?Bluejay?, ?the Company?) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage |
|
| January 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 31, 2022 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organi |
|
| December 22, 2021 |
EXHIBIT 2 LOCK-UP AGREEMENT November 9, 2021 Dawson James Securities, Inc., acting as representative to the several underwriters: Re: Underwriting Agreement, dated November 9, 2021, by and between Bluejay Diagnostics, Inc., and Dawson James Securities, Inc., acting as representative to the several underwriters Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the |
|
| December 22, 2021 |
Joint Filing Agreement, dated December 22, 2021, among the Reporting Persons.* EXHIBIT 1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the ?Exchange Act?) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with respect to securities of Bluejay Diagnostics, Inc. |
|
| December 22, 2021 |
BJDX / Bluejay Diagnostics Inc / Dey Indranil - SCHEDULE 13D Activist Investment SC 13D 1 ea152852-13dindrabluejay.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Bluejay Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 095633103 (CUSIP Number) Indranil (Neil) Dey 360 Massachusetts Avenue, Suite 203 Acton, |
|
| December 22, 2021 |
Joint Filing Agreement, dated December 22, 2021, among the Reporting Persons.* EXHIBIT 1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the ?Exchange Act?) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with respect to securities of Bluejay Diagnostics, Inc. |
|
| December 22, 2021 |
BJDX / Bluejay Diagnostics Inc / Wurth Douglas Clark - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Bluejay Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 095633103 (CUSIP Number) Douglas C. Wurth 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 (844) 327-7078 (Name, Address and Telephone N |
|
| December 22, 2021 |
EXHIBIT 2 LOCK-UP AGREEMENT November 9, 2021 Dawson James Securities, Inc., acting as representative to the several underwriters: Re: Underwriting Agreement, dated November 9, 2021, by and between Bluejay Diagnostics, Inc., and Dawson James Securities, Inc., acting as representative to the several underwriters Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the |
|
| December 16, 2021 |
Exhibit 99.1 IMMEDIATE RELEASE Date: December 16, 2021 Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results IL-6 test for sepsis triage on Track for January 2022 FDA Pre-Submission Filing Expanded Testing Program Planned for Q1-Q3 2022 Raised $21.6 million Gross Proceeds in an Upsized IPO Acton, Massachusetts, Dec. 16, 2021 ? Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (?Bluejay?) a |
|
| December 16, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 16, 2021 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) delaware 001-41031 47-3552922 (State or Other Jurisdiction of Incorporation or Organ |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41031 Bluej |
|
| November 16, 2021 |
8-K 1 ea150715-8kbluejay.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 10, 2021 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-41031 47-3552922 (State or |
|
| November 16, 2021 |
Exhibit 4.1 CUSIP NUMBER:095633 111 ISIN NUMBER:US0956331112 CLASS A COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Initial Exercise Date: November 15, 2021 THIS CLASS A COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions her |
|
| November 12, 2021 |
2,160,000 Units consisting of: Common Stock Class A Warrants Class B Warrants PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-260029 and 333-260936 2,160,000 Units consisting of: Common Stock Class A Warrants Class B Warrants This is an initial public offering of units of our securities. Prior to this offering, there has been no public market for shares of our common stock. Each Unit consists of (a) one share of our common stock (or, at the purchaser?s ele |
|
| November 9, 2021 |
As filed with the Securities and Exchange Commission on November 9, 2021 As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. |
|
| November 5, 2021 |
BLUEJAY DIAGNOSTICS, INC. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 November 5, 2021 BLUEJAY DIAGNOSTICS, INC. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 November 5, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Tyler Howes Re: Bluejay Diagnostics, Inc. Registration Statement on Form S-1 Registration No. 333-260029 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Bl |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BLUEJAY DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-3552922 (State of incorporation or organization) (I.R.S. Employer Identification No.) 360 Massachusett |
|
| November 5, 2021 |
November 5, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: Bluejay Diagnostics, Inc. Registration Statement on Form S-1 (Registration No. 333-260029) Concurrence in Acceleration Request Ladies and Gentlemen: Dawson James Securities, Inc. (?Dawson?), as representative of the underwriters for the referenced offering, hereby concurs in |
|
| November 3, 2021 |
Form of IPO Underwriters’ Warrant Exhibit 4.5 UNDERWRITER COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Issue Date: November , 2021 Initial Exercise Date: May , 2022 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| November 3, 2021 |
As filed with the Securities and Exchange Commission November 3, 2021. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BLUEJAY DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 3841 47-3552922 (State or other jurisdiction of incorporation or organization) (Pri |
|
| November 3, 2021 |
Exhibit 4.2 CLASS A COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Initial Exercise Date: , 2021 THIS CLASS A COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| October 27, 2021 |
FWP 1 ea149213-fwpbluejay.htm FREE WRITING PROSPECTUS Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration no. 333 - 260029 Relating to Preliminary Prospectus dated October 25, 2021 Copyright ©2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 2 Issuer Free Writing Prospectus, Cautionary Statement Concerning Forward - looking Statements CAUTIONARY STA |
|
| October 25, 2021 |
Cavas S. Pavri 202.724.6847 [email protected] 100 N. 18th Street Suite 300 Philadelphia, PA 19103 t 202.778.6400 f 202.778.6460 www.schiffhardin.com October 25, 2021 By EDGAR Submission Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Re: Bluejay Diagnostics, Inc. Registration Statement on Form S |
|
| October 25, 2021 |
Exhibit 99.1 BLUEJAY DIAGNOSTICS, INC. CHARTER OF THE AUDIT COMMITTEE Membership The Audit Committee (the ?Committee?) of the board of directors (the ?Board?) of Bluejay Diagnostics, Inc. (the ?Company?) shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the requirements of Rule 10A-3 of the Securities Exchange Act of 1934, as amended, an |
|
| October 25, 2021 |
Exhibit 10.7 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 7, 2021, between Blue Jay Diagnostics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditio |
|
| October 25, 2021 |
Exhibit 10.1 BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN Section 1. Establishment and Purpose. 1.1 The Board of Directors of Bluejay Diagnostics, Inc. (the ?Company?) hereby establishes the Bluejay Diagnostics, Inc. 2021 Stock Plan (the ?Plan?) effective as of July 6, 2021, subject to approval by the Company?s stockholders within one year of the date hereof. 1.2 The purpose of the Plan is to attract |
|
| October 25, 2021 |
Employment Agreement dated July 1, 2021 between Gordon Kinder and Bluejay Diagnostics, Inc. Exhibit 10.4 RESTATED EMPLOYMENT AGREEMENT This RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of July 1, 2021 (the ?Effective Date?), by and between Bluejay Diagnostic, Inc., a Delaware corporation (the ?Company?) having its principal place of business at 360 Massachusetts Ave, Acton, MA 01720, and Gordon Kinder (?Executive?, and the Company and the Executive collectively refe |
|
| October 25, 2021 |
Exhibit 10.8 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of June 7, 2021, between Bluejay Diagnostics, a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Agre |
|
| October 25, 2021 |
EX-14.1 19 fs12021a1ex14-1bluejay.htm CODE OF ETHICS Exhibit 14.1 BLUEJAY DIAGNOSTICS, INC. CODE OF ETHICS Introduction Bluejay Diagnostics, Inc. and each of its subsidiaries (collectively, the “Company”) are committed to the highest standards of ethics and business conduct. The Company conducts its business as a good corporate citizen and complies with all laws, rules and regulations applicable t |
|
| October 25, 2021 |
As filed with the Securities and Exchange Commission October 25, 2021. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BLUEJAY DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 3841 47-3552922 (State or other jurisdiction of incorporation or organization) (Pri |
|
| October 25, 2021 |
Exhibit 4.2 CLASS A COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Initial Exercise Date: , 2021 THIS CLASS A COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| October 25, 2021 |
Specimen Common Stock Certificate Exhibit 4.1 NUMBER NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 095633 103 BLUEJAY DIAGNOSTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE COMMON STOCK OF BLUEJAY DIAGNOSTICS, INC. (THE ?CORPORATION?) transferable on the books of the Corporation |
|
| October 25, 2021 |
Employment Agreement, dated July 1, 2021, between Neil Dey and Bluejay Diagnostics, Inc. Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of July 1, 2021 (the ?Effective Date?), by and between Bluejay Diagnostic, Inc., a Delaware corporation (the ?Company?) having its principal place of business at 360 Massachusetts Ave, Acton, MA 01720, and Neil Dey (?Executive?, and the Company and Executive collectively referred to herein as the ?Part |
|
| October 25, 2021 |
Employment Agreement, dated July 1, 2021, between Jason Cook and Bluejay Diagnostics, Inc. Exhibit 10.5 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of July 1, 2021 (the ?Effective Date?), by and between Bluejay Diagnostic, Inc., a Delaware corporation (the ?Company?) having its principal place of business at 360 Massachusetts Ave, Acton, MA 01720, and Jason Cook (?Executive?, and the Company and the Executive collectively referred to herein as the |
|
| October 25, 2021 |
Exhibit 3.2 Amended and Restated Bylaws of BlueJay Diagnostics, Inc. (a Delaware corporation) Amended and Restated on October 21, 2021 Table of Contents Page Article I?Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II?Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 1 2.5 Not |
|
| October 25, 2021 |
Exhibit 99.2 BLUEJAY DIAGNOSTICS, INC. CHARTER OF THE COMPENSATION COMMITTEE Membership The Compensation Committee (the ?Committee?) of the board of directors (the ?Board?) of Bluejay Diagnostics, Inc. (the ?Company?) shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the rules of the Nasdaq Stock Market. Each member of the Committee must |
|
| October 25, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 SHARES of Common Stock, SHARES of PREFERRED Stock, and Warrants of BLUEJAY DIAGNOSTICS, INC. UNDERWRITING AGREEMENT November , 2021 Dawson James Securities, Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Dawson James Securities, Inc. 1 North Federal Highway, 5th Floor Boca Raton, FL 33432 Ladies and Gentlemen: The undersigned, Bluejay Dia |
|
| October 25, 2021 |
Compensation Committee Charter Exhibit 99.3 BLUEJAY DIAGNOSTICS, INC. CHARTER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE Membership The Nominating and Corporate Governance Committee (the ?Committee?) of the board of directors (the ?Board?) of Bluejay Diagnostics, Inc. (the ?Company?) shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the rules of the Nasdaq S |
|
| October 25, 2021 |
Exhibit 10.2 License and Supply Agreement This License and Supply Agreement (this ?Agreement?) is made as of the 6th of October, 2020 by and between Bluejay Diagnostics, having its principal place of business at 360 Massachusetts Avenue, Suite 203, Acton, MA, 01720, USA (?Bluejay?) and Toray Industries, Inc., having its principal place of business at 1-1, Nihonbashi-muromachi 2-chome, Chuo-ku, Tok |
|
| October 25, 2021 |
Form of Warrant Agency Agreement Exhibit 4.4 BLUEJAY DIAGNOSTICS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of , 2021 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2021 (?Agreement?), between Bluejay Diagnostics, Inc., a Delaware corporation (the ?Company?), and Continental Stock Transfer & Trust Company (the ?Warrant Agent?). W I T N E S S E T H WHE |
|
| October 25, 2021 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLUEJAY DIAGNOSTICS, INC. October 22, 2021 BlueJay Diagnostics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is BlueJay Diagnostics, Inc. The original certificate of incorporation of the Corporation was filed with |
|
| October 25, 2021 |
EX-21.1 20 fs12021a1ex21-1bluejay.htm LIST OF SUBSIDIARIES Exhibit 21.1 List of Subsidiaries Bluejay Spinco, LLC – Delaware limited liability company – wholly owned |
|
| October 25, 2021 |
Exhibit 10.9 AMENDMENT TO LICENSE AND SUPPLY AGREEMENT This amendment (?Amendment?), dated as of July 21, 2021, is to that certain License and Supply Agreement (the ?Agreement?) dated October 6, 2020 by and between Toray Industries, Inc. (?Toray?) and Bluejay Diagnostics, Inc. (?Bluejay?). Capitalized terms used and not otherwise defined herein shall have the meanings assigned to such terms in the |
|
| October 25, 2021 |
Exhibit 4.3 CLASS B COMMON STOCK PURCHASE WARRANT BLUEJAY DIAGNOSTICS, INC. Warrant Shares: Initial Exercise Date: , 2021 THIS CLASS B COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| October 25, 2021 |
Employment Agreement, dated July 1, 2021, between Kevin Vance and Bluejay Diagnostics, Inc. Exhibit 10.6 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of July 1, 2021 (the ?Effective Date?), by and between Bluejay Diagnostic, Inc., a Delaware corporation (the ?Company?) having its principal place of business at 360 Massachusetts Ave, Acton, MA 01720, and Kevin Vance (?Executive?, and the Company and the Executive collectively referred to herein as th |
|
| October 4, 2021 |
S-1 1 fs12021bluejay.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission October 4, 2021. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BLUEJAY DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 3841 47-3552922 (State or other jurisdiction of incorpo |
|
| October 4, 2021 |
CORRESP 1 filename1.htm 100 N. 18th Street Suite 300 Philadelphia, PA 19103 t 202.778.6400 f 202.778.6460 www.schiffhardin.com Cavas S. Pavri 202.724.6847 [email protected] October 4, 2021 By EDGAR Submission Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Re: Bluejay Diagnostics, Inc. Amendment |
|
| October 4, 2021 |
Exhibit 99.4 CONSENT OF GARY GEMIGNANI In connection with the filing by Bluejay Diagnostics, Inc. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors for Bluejay Diagnostics, Inc. i |
|
| September 8, 2021 |
DRSLTR 1 filename1.htm Cavas S. Pavri 202.724.6847 [email protected] 100 N. 18th Street Suite 300 Philadelphia, PA 19103 t 202.778.6400 f 202.778.6460 www.schiffhardin.com September 8, 2021 By EDGAR Submission Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Re: Bluejay Diagnostics, Inc. Draft Re |
|
| September 8, 2021 |
DRS/A 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012 on September 8, 2021. This amendment no 1 to the draft registration statement has not been publicly filed with the SEC and all information herein remains strictly confidential. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wash |
|
| July 22, 2021 |
DRS 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012 on July 22, 2021. This draft registration statement has not been publicly filed with the SEC and all information herein remains strictly confidential. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 |
|
| July 22, 2021 |
EX-99.4 2 filename2.htm Exhibit 99.4 CONSENT OF GARY GEMIGNANI In connection with the filing by Bluejay Diagnostics, Inc. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors for Blu |
